Highlights and Quick Summary
- EBITDA Margin for the quarter ending June 30, 2022 was -3.65% (a -9.43% decrease compared to previous quarter)
- Year-over-year quarterly EBITDA Margin decreased by -178.33%
- Annual EBITDA Margin for 2021 was -1.28% (a -123.62% decrease from previous year)
- Annual EBITDA Margin for 2020 was 5.42% (a -85.15% decrease from previous year)
- Annual EBITDA Margin for 2019 was 36.49% (a 39.27% increase from previous year)
- Twelve month EBITDA Margin ending June 30, 2022 was -3.49% (a 21.6% increase compared to previous quarter)
- Twelve month trailing EBITDA Margin decreased by -122.6% year-over-year
Trailing EBITDA Margin for the last four month:
| 30 Jun '22 | 31 Mar '22 | 31 Dec '21 | 30 Sep '21 |
|---|---|---|---|
| -3.49% | -2.87% | 3.06% | 15.44% |
Visit stockrow.com/ANIK
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA Margin of Anika Therapeutics Inc.
Most recent EBITDA Marginof ANIK including historical data for past 10 years.Interactive Chart of EBITDA Margin of Anika Therapeutics Inc.
Anika Therapeutics Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | -3.65% | -4.03% | – | – | – |
| 2021 | -11.75% | 4.66% | -1.21% | 21.42% | -1.28% |
| 2020 | 41.64% | -6.86% | -10.07% | 85.88% | 5.42% |
| 2019 | 23.87% | 44.68% | 42.7% | 27.82% | 36.49% |
| 2018 | 40.32% | 37.65% | 41.55% | -29.91% | 26.2% |
| 2017 | 36.73% | 42.2% | 55.99% | 38.57% | 44.1% |
| 2016 | 47.68% | 56.48% | 54.28% | 52.29% | 52.56% |
| 2015 | 58.4% | 59.58% | 58.25% | 41.35% | 55.82% |
| 2014 | 56.84% | 52.12% | 62.3% | 73.71% | 62.65% |
| 2013 | 54.69% | 51.11% | 50.25% | 40.75% | 49.78% |
| 2012 | 39.6% | 26.47% | 37.35% | 28.2% | 33.97% |
| 2011 | 32.39% | 31.53% | – | – | 27.74% |
Business Profile of Anika Therapeutics Inc.
Sector: Healthcare
Industry: Medical Devices